A possible way in which extracellular Ca2+ may modulate the intracehlar flux of Ca2+ is via an effect on platelet cyclic. nucleotide metabolism.
Although it is widely accepted that an increase in cyclic AMP production results in an inhibition of platelet function (Mills & Smith, 1971; Best et al., 1977) little is known concerning the role of cyclic GMP in the platelet. In several tissues, an increase in cyclic GMP often occurs under conditions that oppose an increase in cyclic AMP (Goldberg et al., 1973) and it has been suggested that platelet aggregation may be accompanied by an increase in cyclic GMP concentrations in response to several agents (Jakobs et al., 1974; Davies et al., 1976; Glass et al., 1977) . In addition, Chiang et al. (1976) have provided evidence that platelet aggregation was enhanced in the presence of cyclic GMP.
To further examine the possibility that cyclic GMP may be a messenger in the initiation of platelet function, we have studied the conditions under which changes in cyclic GMP occur and also investigated the effects of cyclic GMP on certain aspects of platelet function. Cyclic GMP was measured by a specific and (1977) , who suggested that the formation of prostaglandin endoperoxides was a prerequisite for cyclic GMP production. The non-aggregatory fatty acid dihomo-y-linoleate produced a similar increase in platelet cyclic GMP ( Table I) , suggesting that an increase in cyclic G M P production may be associated with the peroxidation of unsaturated fatty acids. In support of this hypothesis, stearate was found to have no significant effect on platelet cyclic GMP production. These results are consistent with those of Hidaka & Asano (1977) , who demonstrated a stimulation of human platelet guanylate cyclase by unsaturated fatty acid peroxides. None of the other platelet-aggregating agents tested were found to produce any significant change in platelet cyclic GMP concentrations. Prostaglandins E,, E, and F,, were also without effect. The effects of cyclic GMP and dibutyryl cyclic GMP were examined on platelet aggregation and on 5-hydroxyI1'Cltryptamine secretion. Preincubation of platelets for 2min in the presence of dibutyryl cyclic GMP (0.1-l.OmM) inhibited platelet aggregation and 5-hydroxytryptamine secretion in response to ADP, adrenaline or collagen. Cyclic GMP produced a similar, though less potent, inhibition of platelet function.
In general, the inhibitory effect of dibutyryl cyclic GMP was comparable with, though less marked than, that of dibutyryl cyclic AMP. This suggests that cyclic GMP may inhibit platelet aggregation and secretion by mimicking cyclic AMP and thus by activating a cyclic AMP-dependent protein kinase (Pareti et al., 1978) . Cyclic AMP is known to inhibit the production by platelets of thromboxane B,, probably by limiting the availability of endogenous arachidonate (Minkes et al.. 1977) . We found that both cyclic AMP and cyclic GMP were able to inhibit thromboxane B, production by washed human platelets in response to thrombin. Thus it is possible that cyclic GMP, in common with cyclic AMP, may impair platelet function at least in part by inhibiting the liberation of arachidonate from platelet phospholipid.
In conclusion, our results indicate that platelet cyclic GMP concentrations were not related to aggregation or secretion and thus cyclic GMP is probably not an important messenger in platelet activation. Furthermore, cyclic GMP was found to be a weak inhibitor of platelet aggregation, secretion and thromb- The monoamine octopamine has been shown to be widely distributed in the nervous tissues of invertebrates (see Robertson & Juorio, 1976) , and some of its effects resemble those of catecholamines in vertebrates. Previous experiments (Candy, 1978) have shown that the oxidation of substrates by perfused locust flight muscle is stimulated by DL-octopamine. However, it was not established whether the octopamine receptors were specific for the D-or the L-form of the amine. Since locust haemolymph has now been shown to contain the o-isomer (Goosey & Candy, 1980) , it was important to establish whether the muscles respond to D-octopamine. Results of experiments designed to test this are reported in the present communication.
Octapamine also has a modulatory action on the myogenic rhythm of locust leg muscle (Evans & OShea, 1978) and can stimulate adenylate cyclase from lobster blood cells (Batelle & Kravitz, 1978) and cockroach brain (Harmer & Horn, 1977) . The receptors of these tissues resemble the a-adrenergic receptors of mammals, as shown by effects of drugs that are known to selectively block a-or 8-type responses in mammalian systems. We now report the effects of such drugs on the oxidative metabolism of locust flight muscle.
The oxidation of [U-14Clglucose to 14C0, by working locust (Schlstocerca americana gregaria) thoracic muscle was followed by using methods previously described (Candy, 1970 (Candy, , 1978 . A mixed substrate of 0 . 0 8~-[~~C ] g~U o s S e and 0.1 Mbutyrate (unlabelled) was used, and perfusion was performed until the rate of appearance of 14C0, reached a steady state (60-80min). This was taken as the control rate of oxidation. The compound under test was then added to the perfusion medium, and the oxidation rate was followed for a further 30 min. Where appropriate, D-octopamine was then added and the perfusion was continued for 30min.
The method of Kappe & Armstrong (1964) The /.?-blockers propranolol and dichloroisoproterenol do not markedly inhibit octopamine stimulation of oxidation (Table 1) . but the a-blocker phentolamine almost completely inhibits the action of octopamine. However, phenoxybenzamine stimulated muscle metabolism in the absence of octopamine and failed to 
